Eurofins-Cerep

Eurofins Discovery has provided drug discovery products and services for over 40 years, expanding its portfolio through acquisitions.

Eurofins Discovery scientists use their biology expertise to recommend assays for specific therapeutic areas or target classes.

G protein-coupled receptors (GPCRs) remain one of the most important classes of drug targets, yet their structural complexity and dynamic signaling behavior continue to challenge traditional discovery approaches.

The Scientific Advisory Board includes experts from pharmaceutical and biotechnology industries.

We are a global leader in scientific testing and laboratory services for advancement of drug discovery and human health.

Gain access to our industry-leading products and services across three continents: USA, EUROPE and ASIA.

Our drug discovery experts would be happy to respond to your request – please tell us how we can help!

The page organizes Eurofins Discovery’s capabilities and services portfolio for easier navigation.

Eurofins Cerep reports **EUR21.55 million in revenue** for the first half of 2026, an **18.2% increase** from the prior period. The company’s growth stems entirely from service activities, including drug discovery and biophysics. Net income for the period reaches **EUR4.8 million**, reflecting strong financial performance in its core markets.

Sep 2026Ideal InvestisseurNews article

Eurofins-Cerep SA reports **EUR 42.1 million in revenue** for 2025, a decline from **EUR 44.31 million** in 2024. The company also records **net income of EUR 4.78 million** for the year. Financial results reflect a contraction in annual revenue while maintaining profitability.

Apr 2026MarketScreenerNews article

Eurofins-Cerep SA reports **EUR 20.26 million in revenue** for the first half of 2025, a decline from **EUR 21.91 million** in the same period of 2024. The company also records **net income of EUR 1.82 million** for the half-year. The results reflect a year-over-year revenue decrease amid ongoing market conditions.

Oct 2025MarketScreenerNews article

Eurofins-Cerep SA reports **EUR 44.31 million in 2024 revenue**, down from EUR 48 million in 2023. The company also announces **net income of EUR 7.15 million** for the year. The earnings reflect a decline in annual revenue while maintaining profitability through cost management or operational adjustments.

Apr 2025MarketScreenerNews article